Mergers & Acquisitions
Greenhill's M&A practice includes some of the most experienced professionals in the industry. Drawing on that experience, we are active across the full range of M&A advisory roles:
Leveraging our independence and lack of conflicts, we have a strong track record in sell side advisory roles. Acting for target companies, special board committees or selling shareholders, we can operate at the heart of any process, assist in negotiations and give impartial and objective advice about the merits of bids received.
We have a strong record of successful buy side advisory assignments in relation to public or private target companies and are able to advise interested buyers on attractive targets through our global network of relationships.
Greenhill is well qualified to assist clients on merger transactions given the long experience of its partners and professionals, an assurance of total discretion and a lack of conflicting interests. Greenhill has a number of sizeable mergers in its list of completed transactions both in the US and internationally.
Various advisory work that we undertake does not fit a conventional ‘transaction’ definition. Examples include our work advising the Australian National Rugby League Commission on the sale of television broadcast rights and work for the global partnership of Arthur Andersen in the immediate aftermath of the cases that followed the collapse of Enron. We believe that Greenhill’s independence, experience, expertise and discretion positions us well for special advisory assignments.
Greenhill’s network of international offices and our ‘single Firm’ operating model allow us to offer clients a seamless cross-border advisory service with a truly global perspective.
Advised Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, on the acquisition of a proprietary regenerative medicine products company BioD, LLC and a concurrent private placement.
U.S. rights to 37 approved and 5 pipeline generic products
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to 42 generic products
U.S. rights to an authorized generic version of Adderall XR
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to an authorized generic version of Adderall XR
Served as independent financial advisor to the Board of Directors of Gannett in connection with its acquisition of ReachLocal
U.S. rights to a broad portfolio of 18 generic products from Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the U.S. rights to a broad portfolio of 18 generic products to Impax Laboratories, Inc.